Indivior (NASDAQ:INDV) PT Lowered to $16.00 at Craig Hallum

Indivior (NASDAQ:INDV) had its target price lowered by Craig Hallum from $20.00 to $16.00 in a research report report published on Friday, Benzinga reports. The firm currently has a buy rating on the stock.

Separately, Piper Sandler reiterated an overweight rating and issued a $15.00 target price (down previously from $22.00) on shares of Indivior in a research note on Friday.

Indivior Stock Performance

Shares of NASDAQ INDV opened at $7.90 on Friday. Indivior has a 12 month low of $7.33 and a 12 month high of $23.22. The company has a quick ratio of 0.68, a current ratio of 0.85 and a debt-to-equity ratio of 23.50. The company has a market cap of $1.09 billion, a P/E ratio of 790.00 and a beta of 0.68. The business’s 50 day moving average is $10.88 and its two-hundred day moving average is $14.52.

Indivior (NASDAQ:INDV) last announced its earnings results on Thursday, July 25th. The company reported $0.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.40 by $0.04. Indivior had a negative net margin of 12.29% and a negative return on equity of 654.82%. The business had revenue of $299.00 million for the quarter, compared to analyst estimates of $285.90 million. On average, equities analysts expect that Indivior will post 1.7 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Cubist Systematic Strategies LLC increased its holdings in Indivior by 32.0% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 25,236 shares of the company’s stock valued at $407,000 after buying an additional 6,121 shares during the period. Susquehanna International Group Ltd. acquired a new stake in shares of Indivior during the 2nd quarter valued at about $3,224,000. Millennium Management LLC increased its stake in Indivior by 48.1% in the second quarter. Millennium Management LLC now owns 493,313 shares of the company’s stock valued at $7,952,000 after acquiring an additional 160,282 shares during the period. Marshall Wace LLP raised its position in Indivior by 493.2% in the second quarter. Marshall Wace LLP now owns 73,732 shares of the company’s stock worth $1,189,000 after purchasing an additional 61,302 shares in the last quarter. Finally, XTX Topco Ltd bought a new position in Indivior during the second quarter worth about $249,000. 60.33% of the stock is owned by institutional investors.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.